Project

Nanopore sequencing of complete pharmacogenes after CRISPR/Cas9 enrichment in tamoxifen and clopidogrel patients allowing enhanced haplotyping and continuous scale machine learning efficacy prediction.

Code

01D04221

Duration

01 October 2021 → 30 September 2025

Funding

Regional and community funding: Special Research Fund

Promotor

Filip Van Nieuwerburgh

Research disciplines

Medical and health sciences
- Pharmogenetics and -genomics

Keywords

Pharmacogenetics haplotypng nanopore sequencing machine learning

Project description

Pharmacogenetics (PGx) studies how genes influence individual response to drug therapies. Current massively parallel short-read DNA sequencing (SR-MPS) technologies provide limited haplotype information. We want to alleviate this by developing full-gene long-read MPS on PGx genes using an amplification-free CRISPR/Cas9 target enrichment method. Completely-phased genotype data and metadata from 2 cohorts will be used to train a machine learning model.Pharmacogenetics (PGx) studies how genes influence individual response to drug therapies. Current massively parallel short-read DNA sequencing (SR-MPS) technologies provide limited haplotype information. We want to alleviate this by developing full-gene long-read MPS on PGx genes using an amplification-free CRISPR/Cas9 target enrichment method. Completely-phased genotype data and metadata from 2 cohorts will be used to train a machine learning model.